Expression and Clinical Significance of Co-inhibitory Molecules TIGIT/CD155 and PD-1 in Chronic Lymphocytic Leukemia
10.19746/j.cnki.issn1009-2137.2025.01.008
- VernacularTitle:共抑制分子TIGIT/CD155和PD-1在慢性淋巴细胞白血病中的表达及临床意义
- Author:
Rui ZHANG
1
;
Shuang CHEN
1
;
Ting-Ting LUO
1
;
Jian-Hua QU
1
Author Information
1. 新疆医科大学第一附属医院血液病中心实验室,新疆维吾尔自治区血液病研究所,新疆乌鲁木齐 830054
- Publication Type:Journal Article
- Keywords:
chronic lymphocytic leukemia;
inhibitory molecule;
PD-1;
TIGIT
- From:
Journal of Experimental Hematology
2025;33(1):54-61
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression of co-inhibitory molecules TIGIT/CD155 and PD-1 on CD4+T cells and Treg cells in peripheral blood of patients with chronic lymphocytic leukemia(CLL)and analyze their clinical significance.Methods:The expression of PD-1 and TIGIT on CD4+T cells and Treg cells was detected by flow cytometry in 40 CLL patients and 20 healthy controls.Additionally,the expression of CD 155 on peripheral blood B cells and DC cells of the enrolled subjects was detected.Results:The proportions of PD-1+TIGIT+CD4+T cells,PD-1+TIGIT+Treg cells and CD155+DC cells in peripheral blood of CLL patients were significantly higher than those of healthy controls(P＜0.05).The proportions of PD-1+TIGIT+CD4+T cells and PD-1+TIGIT+Treg cells in CLL patients were significantly higher than those of PD-1+TIGIT-CD4+T cells and PD-1+TIGIT-Treg cells,respectively(P＜0.05).Both PD-1+TIGIT+CD4+T cells and PD-1+TIGIT+Treg cells were positively correlated with the level of CD155+DC cells(r=0.742,r=0.766).With the progression of Binet stage,the proportions of PD-1+TIGIT+CD4+T cells,PD-1+TIGIT+Treg cells,and CD155+DC cells gradually increased(P＜0.05),and the aforementioned three types cells were all increased in patients with CD38≥30％,IGVH unmutated,or poor prognosis due to chromosomal abnormalities(P＜0.05).Conclusion:Co-inhibitory molecules PD-1 and TIGIT may be involved in immunodepletion in patients with advanced CLL,which has clinical prognostic value.Dual inhibitor molecular targeted therapy provides a new direction for the individualized treatment of CLL.
